Owen Witte, MD
Owen Witte received his undergraduate degree from Cornell and his MD from Stanford University where he trained with Irv Weissman. He completed postdoctoral research at MIT in the laboratory of David Baltimore. In 1980 he joined the faculty at UCLA where he presently is an Investigator of the Howard Hughes Medical Institute, Professor of Microbiology, Immunology and Molecular Genetics where he holds the President's Chair in Developmental Immunology, and Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA.
He has made significant contributions to the understanding of human leukemias and immune disorders. His work includes the discovery of tyrosine kinase activity in the viral ABL gene and the demonstration of the BCR-ABL oncoproteins in Philadelphia chromosome positive human chronic myelogenous leukemia and acute lymphocytic leukemia, and demonstration of their critical role in the pathology of these diseases. His work also lead to the co-discovery of Bruton's tyrosine kinase which is required for normal B-lymphocyte development which when mutated leads to X-linked agammagloblulinemia. This has had practical impact in leading to the development of STI-571 (Gleevec) as an effective treatment for human chronic myelogenous leukemia and defining new pathways and targets for the treatment of immune disorders.
He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Academy of Microbiology and was recently elected to the Institute of Medicine. Dr. Witte has received recognition for his research including the Milken Foundation Award in Basic Cancer Research, the Rosenthal Award of the American Association for Cancer Research, the Dameshek Prize of the American Society of Hematology, the Alpert Foundation Prize, and most recently The Leukemia and Lymphoma Society's de Villiers International Achievement Award for his work. Dr. Witte currently serves on the editorial boards of Cell, Cancer Cell, Journal of Clinical Investigation and several other journals. He is active with multiple foundations and advisory boards including the Pew Scholars in Biomedical Science, The Damon Runyon Scholars Board, Lasker Award Jury and the Prostate Cancer Foundation Research grants program. Dr. Witte has a long-standing interest in the education of physician scientists, and recently became Director of the UCLA Medical Scientist Training Program that provides combined MD and PhD training for highly selected medical students.
| Publications: | Wang, L., Radu, C. G., Yang, L. V., Bentolila, L. A., Riedinger, M., Witte, O. N. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol Biol Cell. 2005; 16(5): 2234-37. Xin, L., Lawson, D. A., Witte, O. N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A. 2005; 102(19): 6942-7. Kim, Y. J. Dubey, P. Ray, P. Gambhir, S. S. Witte, O. N. Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol. 2004; 6(5): 331-40. Wong, S. Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004; 22: 247-306. Whyburn, L. R. Halcomb, K. E. Contreras, C. M. Pappu, R. Witte, O. N. Chan, A. C. Satterthwaite, A. B. Haploinsufficiency of B cell linker protein enhances B cell signaling defects in mice expressing a limiting dosage of Bruton's tyrosine kinase. Int Immunol. 2003; 15(3): 383-92. Le, L.Q., Kabarowski, J.H.S., Wong, S., Nguyen, K., Gambhir, S.S., Witte, O.N Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell. 2002; 1(4): 381-391. Le, L.Q., Kabarowski, J.H.S., Weng, Z., Satterthwaite, A.B., Harvill, E.T., Jensen, E.R., Miller, J.F. and Witte, O.N Mice lacking the orphan G protein-coupled receptor, G2A, develop a late-onset autoimmune syndrome. Immunity. 2001; 14(5): 561-571. Xin, L., Lawson, D. A., Witte, O. N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A. 2005; 102(19): 6942-7. Radu, C. G. Nijagal, A. McLaughlin, J. Wang, L. Witte, O. N. Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. Proc Natl Acad Sci U S A. 2005; 102(5): 1632-7. Yang, L. V. Radu, C. G. Wang, L. Riedinger, M. Witte, O. N. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood. 2005; 105(3): 1127-34. Wong, S. McLaughlin, J. Cheng, D. Zhang, C. Shokat, K. M. Witte, O. N. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A. 2004; 101(50): 17456-61. Guo, S. Ferl, G. Z. Deora, R. Riedinger, M. Yin, S. Kerwin, J. L. Loo, J. A. Witte, O. N. A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation. Proc Natl Acad Sci U S A. 2004; 101(39): 14180-5. Yu, P. W. Tabuchi, R. S. Kato, R. M. Astrakhan, A. Humblet-Baron, S. Kipp, K. Chae, K. Ellmeier, W. Witte, O. N. Rawlings, D. J. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood. 2004; 104(5): 1281-90. Kharas, M. G. Deane, J. A. Wong, S. O'Bosky, K. R. Rosenberg, N. Witte, O. N. Fruman, D. A. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004; 103(11): 4268-75. Radu, C. G. Yang, L. V. Riedinger, M. Au, M. Witte, O. N. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci U S A. 2004; 101(1): 245-50. Wong, S. McLaughlin, J. Cheng, D. Shannon, K. Robb, L. Witte, O. N. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci U S A. 2003; 100(20): 11630-5. Xin, L. Ide, H. Kim, Y. Dubey, P. Witte, O. N. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A. 2003; 100 Suppl 1: 11896-903. Ferl, G. Z. Timmerman, J. M. Witte, O. N. Extending the utility of gene profiling data by bridging microarray platforms. Proc Natl Acad Sci U S A. 2003; 100(19): 10585-7. Whyburn, L. R. Halcomb, K. E. Contreras, C. M. Lowell, C. A. Witte, O. N. Satterthwaite, A. B. Reduced dosage of Bruton's tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. J Immunol. 2003; 171(4): 1850-8. Wong, S. McLaughlin, J. Cheng, D. Witte, O. N. Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood. 2003; 101(10): 4088-97. Dubey, P. Su, H. Adonai, N. Du, S. Rosato, A. Braun, J. Gambhir, S. S. Witte, O. N. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A. 2003; 100(3): 1232-7. Watabe, T., Lin, M., Ide, H., Donjacour, A.A., Cunha, G.R., Witte, O.N., Reiter, R.E Growth Regeneration and Tumorigenesis of the Prostate Activates the PSCA promotor. Proc. Nat. Acad. Sci.. 2002; 99(1): 401-406. Saffran, D.C. Raitano, A.B Hubert, R.S. Witte, O.N. Reiter, R.E. Jakobovits, A Anti-PSCA monoclonal antibodies inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.. Proc. Nat. Acad. Sci.. 2001; 98(5): 2658-2663. Satterthwaite, A.B., Willis, F, Kanchanastit, P., Fruman, D. Cantely, L.C., Helgason, C.D., Humphries, R.K., Lowell, C.A., Simon, M. Leitges, M., Tarakhovsky, A., Tedder, T.F., Lesche, R., Wu, H. and Witte, O.N A sensitized genetic system for the analysis of Murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proc. Nat. Acad. Sci.. 2000; 97(12): 6692-6697. Era, T., and Witte, O.N Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Nat. Acad. Sci. 2000; 97(4): 1737-1742. |
